The pathobiologic features of carcinomas of type II pneumocytes. An immunocytologic study

Gurmukh Singh, Bernd W. Scheithauer, Sikandar L. Katyal

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Adenocarcinomas of the lung without squamous differentiation or obvious mucus production from 51 patients were studied. Twenty‐eight tumors (55%), when stained with rabbit anti‐human surfactant apoprotein antiserum by the peroxidase‐antiperoxidase method, demonstrated characteristic nuclear inclusions. Most of these tumors could be identified histochemically by the presence of eosinophilic, periodic acid‐Schiff (PAS)‐positive nuclear inclusions. In patients with apoprotein‐immunoreactive tumors there were nine deaths due to tumor (32%) within 5 years of diagnosis. Eight of the nine deaths occurred in patients whose tumors exceeded 3 cm in diameter; an equal number of patients were smokers. The average age of patients with apoprotein‐positive tumors was 67.3 years, a figure greater than that for patients with apoprotein‐negative tumors (61.4 years). Five of the 23 patients with apoprotein‐negative tumors died of their neoplasms; in two of the subjects the tumors exceeded 3 cm in diameter. In that no significant difference in survival was observed in patients with apoprotein‐positive and apoprotein‐negative tumors, it was concluded that subclassification of adenocarcinomas of the lung as apoprotein‐positive, i.e., type II pneumocytic, or as apoprotein‐negative, is of no clinical or prognostic significance. Nonetheless, peripheral tumors measuring less than 3 cm in size and showing neither squamous differentiation nor obvious mucus production should be recognized as a prognostically favorable group in comparison with other types of lung carcinomas.

Original languageEnglish (US)
Pages (from-to)994-999
Number of pages6
JournalCancer
Volume57
Issue number5
DOIs
StatePublished - Jan 1 1986
Externally publishedYes

Fingerprint

Alveolar Epithelial Cells
Carcinoma
Neoplasms
Intranuclear Inclusion Bodies
Mucus
Apoproteins
Surface-Active Agents
Immune Sera

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The pathobiologic features of carcinomas of type II pneumocytes. An immunocytologic study. / Singh, Gurmukh; Scheithauer, Bernd W.; Katyal, Sikandar L.

In: Cancer, Vol. 57, No. 5, 01.01.1986, p. 994-999.

Research output: Contribution to journalArticle

Singh, Gurmukh ; Scheithauer, Bernd W. ; Katyal, Sikandar L. / The pathobiologic features of carcinomas of type II pneumocytes. An immunocytologic study. In: Cancer. 1986 ; Vol. 57, No. 5. pp. 994-999.
@article{eef1490766874562b4d5be3eadafcea9,
title = "The pathobiologic features of carcinomas of type II pneumocytes. An immunocytologic study",
abstract = "Adenocarcinomas of the lung without squamous differentiation or obvious mucus production from 51 patients were studied. Twenty‐eight tumors (55{\%}), when stained with rabbit anti‐human surfactant apoprotein antiserum by the peroxidase‐antiperoxidase method, demonstrated characteristic nuclear inclusions. Most of these tumors could be identified histochemically by the presence of eosinophilic, periodic acid‐Schiff (PAS)‐positive nuclear inclusions. In patients with apoprotein‐immunoreactive tumors there were nine deaths due to tumor (32{\%}) within 5 years of diagnosis. Eight of the nine deaths occurred in patients whose tumors exceeded 3 cm in diameter; an equal number of patients were smokers. The average age of patients with apoprotein‐positive tumors was 67.3 years, a figure greater than that for patients with apoprotein‐negative tumors (61.4 years). Five of the 23 patients with apoprotein‐negative tumors died of their neoplasms; in two of the subjects the tumors exceeded 3 cm in diameter. In that no significant difference in survival was observed in patients with apoprotein‐positive and apoprotein‐negative tumors, it was concluded that subclassification of adenocarcinomas of the lung as apoprotein‐positive, i.e., type II pneumocytic, or as apoprotein‐negative, is of no clinical or prognostic significance. Nonetheless, peripheral tumors measuring less than 3 cm in size and showing neither squamous differentiation nor obvious mucus production should be recognized as a prognostically favorable group in comparison with other types of lung carcinomas.",
author = "Gurmukh Singh and Scheithauer, {Bernd W.} and Katyal, {Sikandar L.}",
year = "1986",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19860301)57:5<994::AID-CNCR2820570520>3.0.CO;2-2",
language = "English (US)",
volume = "57",
pages = "994--999",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - The pathobiologic features of carcinomas of type II pneumocytes. An immunocytologic study

AU - Singh, Gurmukh

AU - Scheithauer, Bernd W.

AU - Katyal, Sikandar L.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - Adenocarcinomas of the lung without squamous differentiation or obvious mucus production from 51 patients were studied. Twenty‐eight tumors (55%), when stained with rabbit anti‐human surfactant apoprotein antiserum by the peroxidase‐antiperoxidase method, demonstrated characteristic nuclear inclusions. Most of these tumors could be identified histochemically by the presence of eosinophilic, periodic acid‐Schiff (PAS)‐positive nuclear inclusions. In patients with apoprotein‐immunoreactive tumors there were nine deaths due to tumor (32%) within 5 years of diagnosis. Eight of the nine deaths occurred in patients whose tumors exceeded 3 cm in diameter; an equal number of patients were smokers. The average age of patients with apoprotein‐positive tumors was 67.3 years, a figure greater than that for patients with apoprotein‐negative tumors (61.4 years). Five of the 23 patients with apoprotein‐negative tumors died of their neoplasms; in two of the subjects the tumors exceeded 3 cm in diameter. In that no significant difference in survival was observed in patients with apoprotein‐positive and apoprotein‐negative tumors, it was concluded that subclassification of adenocarcinomas of the lung as apoprotein‐positive, i.e., type II pneumocytic, or as apoprotein‐negative, is of no clinical or prognostic significance. Nonetheless, peripheral tumors measuring less than 3 cm in size and showing neither squamous differentiation nor obvious mucus production should be recognized as a prognostically favorable group in comparison with other types of lung carcinomas.

AB - Adenocarcinomas of the lung without squamous differentiation or obvious mucus production from 51 patients were studied. Twenty‐eight tumors (55%), when stained with rabbit anti‐human surfactant apoprotein antiserum by the peroxidase‐antiperoxidase method, demonstrated characteristic nuclear inclusions. Most of these tumors could be identified histochemically by the presence of eosinophilic, periodic acid‐Schiff (PAS)‐positive nuclear inclusions. In patients with apoprotein‐immunoreactive tumors there were nine deaths due to tumor (32%) within 5 years of diagnosis. Eight of the nine deaths occurred in patients whose tumors exceeded 3 cm in diameter; an equal number of patients were smokers. The average age of patients with apoprotein‐positive tumors was 67.3 years, a figure greater than that for patients with apoprotein‐negative tumors (61.4 years). Five of the 23 patients with apoprotein‐negative tumors died of their neoplasms; in two of the subjects the tumors exceeded 3 cm in diameter. In that no significant difference in survival was observed in patients with apoprotein‐positive and apoprotein‐negative tumors, it was concluded that subclassification of adenocarcinomas of the lung as apoprotein‐positive, i.e., type II pneumocytic, or as apoprotein‐negative, is of no clinical or prognostic significance. Nonetheless, peripheral tumors measuring less than 3 cm in size and showing neither squamous differentiation nor obvious mucus production should be recognized as a prognostically favorable group in comparison with other types of lung carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=0022640014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022640014&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19860301)57:5<994::AID-CNCR2820570520>3.0.CO;2-2

DO - 10.1002/1097-0142(19860301)57:5<994::AID-CNCR2820570520>3.0.CO;2-2

M3 - Article

C2 - 2417691

AN - SCOPUS:0022640014

VL - 57

SP - 994

EP - 999

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -